Medical Cannabis Use in France: An Observational Safety Study Based on the RECANN Registry and the Pharmacovigilance/Addictovigilance System From 2021 to 2024

20260 citationsJournal Article

Authors

Cécile Chevallier · Hospices Civils de Lyon

Anne Batisse · Assistance Publique – Hôpitaux de Paris

Emilie Monzon · Agence Nationale de Sécurité du Médicament et des Produits de Santé

Nathalie Richard · Agence Nationale de Sécurité du Médicament et des Produits de Santé

Nicolas Authier · Inserm

Chouki Chenaf · Centre Hospitalier Universitaire de Clermont-Ferrand

Louise Gaboriau

Abstract

During the experimentation, 3% of patients treated with MC experienced at least one serious ADR. The safety profile was dominated by neurological, gastrointestinal, and psychiatric ADRs. Only one case of MC misuse was identified with inflorescences. This study is observational and non-comparative and cannot provide a comprehensive assessment of the risk associated with MC use.

Topics & Keywords

Cannabis and Cannabinoid Research Opioid Use Disorder Treatment Forensic Toxicology and Drug Analysis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Fundamental and Clinical Pharmacology

Volume 40, Issue 2, pp. e70074-e70074

DOI: 10.1111/fcp.70074

Field-Weighted Citation Impact: 0.00